E-MAIL: your-email@mail.com
E-MAIL: your-email@mail.com
Qilu will supply IV pembrolizumab biosimilar to Orion Pharma and will be entitled to receive a share of the profits generated by Orion Pharma, as well as certain development, regulatory and sales milestone payments.
imphoenix82
DualityBio will generate and develop ADCs against oncology targets selected by Genentech, using payloads from its DUPAC platform.
imphoenix82
Both Ziihera-containing combinations significantly improved progression-free survival in the overall HER2+ gastroesophageal adenocarcinoma patients, reducing the risk of disease progression or death by 35 per cent and extending median PFS to 12.4 months versus 8.1 months with trastuzumab plus chemotherapy.
imphoenix82
The approval makes Yochanra the first drug independently developed in China to address the longstanding global challenge of acquired resistance to FGFR inhibitor therapy in patients with cholangiocarcinoma.
imphoenix82
Firefly Bio’s Firelink DAC platform will help advance Johnson & Johnson’s strategy to develop targeted therapies for some of the most prevalent and difficult-to-treat solid tumours.
imphoenix82HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 9354115542
HealthXploreIndia @2026. All Rights Reserved.
